Back to Directory

Charlotte Perlowski

Email

cperlowski@fhi360.org

Phone

919-321-3581

Institution

FHI 360

Title

Research Associate

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2035/HVTN 604: Phase I/II Study of the Safety and Immunogenicity of VPM1002 Vaccination and BCG Revaccination against Tuberculosis in South African Pre-Adolescents Living with and without HIV (LEAP)

DAIDS Number

38846

Research Area

Tuberculosis

Study Status

In Development

P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure

Study Status

Enrolling

P1100: AERAS 402

DAIDS Number

11801

Research Area

Tuberculosis

Study Status

Concluded

IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children

DAIDS Number

12016

Research Area

Complications & Comorbidities

Study Status

Concluded

IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

38405

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

Show All